Naohiro Watanabe

Five-year prognostic impact of pre-existing interstitial lung disease in non-small cell lung cancer patients treated with anti-PD-1 monotherapy: a retrospective analysis

Teppei Yamaguchi, Junichi Shimizu, Reiko Matsuzawa, Kazuhiro Shimomura et autres

BACKGROUND: Anti-programmed death 1 (PD-1) antibodies, a type of immune checkpoint inhibitor (ICI), have enhanced survival rates in non-small cell lung cancer (NSCLC). While some patients with NSCLC have pre-existing interstitial lung disease (ILD), data on the long-term safety and effectiveness of …

jp (code pays fourni par la source)

Five-year prognostic impact of pre-existing interstitial lung disease in non-small cell lung cancer patients treated with anti-PD-1 monotherapy: a retrospective analysis

Teppei Yamaguchi, Junichi Shimizu, Reiko Matsuzawa, Kazuhiro Shimomura et autres

Abstract Background Anti-programmed death 1 (PD-1) antibodies, a type of immune checkpoint inhibitor (ICI), have enhanced survival rates in non-small cell lung cancer (NSCLC). While some patients with NSCLC have pre-existing interstitial lung disease (ILD), data on the long-term safety and effectiveness …

jp (code pays fourni par la source)

Additional file 1 of Five-year prognostic impact of pre-existing interstitial lung disease in non-small cell lung cancer patients treated with anti-PD-1 monotherapy: a retrospective analysis

Teppei Yamaguchi, Junichi Shimizu, Reiko Matsuzawa, Kazuhiro Shimomura et autres

Supplementary Material 1.

jp (code pays fourni par la source)

Five-year prognostic impact of pre-existing interstitial lung disease in non-small cell lung cancer patients treated with anti-PD-1 monotherapy: a retrospective analysis

Teppei Yamaguchi, Junichi Shimizu, Reiko Matsuzawa, Kazuhiro Shimomura et autres

Abstract Background Anti-programmed death 1 (PD-1) antibodies, a type of immune checkpoint inhibitor (ICI), have enhanced survival rates in non-small cell lung cancer (NSCLC). While some patients with NSCLC have pre-existing interstitial lung disease (ILD), data on the long-term safety and effectiveness …

jp (code pays fourni par la source)

Additional file 1 of Five-year prognostic impact of pre-existing interstitial lung disease in non-small cell lung cancer patients treated with anti-PD-1 monotherapy: a retrospective analysis

Teppei Yamaguchi, Junichi Shimizu, Reiko Matsuzawa, Kazuhiro Shimomura et autres

Supplementary Material 1.

jp (code pays fourni par la source)

Primary collision lung adenocarcinoma harboring EGFR exon 21 L858R and KRAS G12C mutations: A case report

Yutaka Fujiwara, Katsuhiro Masago, Katsutoshi Seto, Yutaro Koide et autres

Pulmonary collision tumors are characterized by the coexistence of two morphologically and genetically distinct neoplasms within a single lesion. We report a rare case of primary collision lung adenocarcinoma harboring two mutually exclusive driver mutations, EGFR exon 21 L858R and KRAS G12C. …

jp (code pays fourni par la source)

Supplementary Table S2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study

Kohei Shitara, Motohiro Tamiya, Kyoichi Okishio, Hisashi Hosaka et autres

Representativeness of study participants

Supplementary Table S3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study

Kohei Shitara, Motohiro Tamiya, Kyoichi Okishio, Hisashi Hosaka et autres

Post-progression anti-cancer therapy of the nivolumab monotherapy

Supplementary Table S1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study

Kohei Shitara, Motohiro Tamiya, Kyoichi Okishio, Hisashi Hosaka et autres

The antibodies list used for TIL analysis

Supplementary Table S1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study

Kohei Shitara, Motohiro Tamiya, Kyoichi Okishio, Hisashi Hosaka et autres

The antibodies list used for TIL analysis

Supplementary Table S2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study

Kohei Shitara, Motohiro Tamiya, Kyoichi Okishio, Hisashi Hosaka et autres

Representativeness of study participants

Supplementary Table S3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study

Kohei Shitara, Motohiro Tamiya, Kyoichi Okishio, Hisashi Hosaka et autres

Post-progression anti-cancer therapy of the nivolumab monotherapy